@dansfera: The pressure on those 'one-and-done' gene therapies is *intense*. Turns out, preventing a complete response letter often hinges on a monitor truly understanding the nuances—like why a patient chews that film or places it differently than intended. That crucial, real-world knowledge trickling down to the site coordinator is the difference between a minor issue and a massive trial failure. Spotting the small deviations in protocol compliance *before* they derail the whole process is where the real heroes work! 🤯 #GeneTherapy #ClinicalTrials #Pharma #MedTech #Compliance